Overview of therapeutic drug monitoring of immunosuppressive drugs: Analytical and clinical practices.
Capillary electrophoresis
Immunoassay
Liquid chromatography
Mass spectrometry
Personalized medicine
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
25 Oct 2021
25 Oct 2021
Historique:
received:
09
04
2021
revised:
16
07
2021
accepted:
05
08
2021
pubmed:
17
8
2021
medline:
6
10
2021
entrez:
16
8
2021
Statut:
ppublish
Résumé
Immunosuppressant drugs (ISDs) play a key role in short-term patient survival together with very low acute allograft rejection rates in transplant recipients. Due to the narrow therapeutic index and large inter-patient pharmacokinetic variability of ISDs, therapeutic drug monitoring (TDM) is needed to dose adjustment for each patient (personalized medicine approach) to avoid treatment failure or side effects of the therapy. To achieve this, TDM needs to be done effectively. However, it would not be possible without the proper clinical practice and analytical tools. The purpose of this review is to provide a guide to establish reliable TDM, followed by a critical overview of the current analytical methods and clinical practices for the TDM of ISDs, and to discuss some of the main practical aspects of the TDM.
Identifiants
pubmed: 34399192
pii: S0731-7085(21)00426-X
doi: 10.1016/j.jpba.2021.114315
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114315Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that there is no conflict of interest.